Spherix to Expand Phase III Diabetes Trial
July 15, 2008
Spherix has reported that the Phase III clinical trial of its potential type 2 diabetes drug, Naturlose, will expand outside of the US.
The company has also announced that it has successfully petitioned the FDA to eliminate the need for pre-mixed solutions for the delivery of study medicine to participants.
Randy Brown, chief of operations at Spherix, said: “This expansion abroad should allow us to finish enrollment in the first quarter of 2009, which is consistent with the timeline reported at the recent shareholders meeting.”